Hyperfine's Portable MRI Shows 92% Concordance in NEURO PMR Study, Surpasses 3,000 Scans
HYPR is trading near its 52-week low of $0.85 (2.6% above the low).
Summary
Hyperfine published the NEURO PMR study in the Journal of Neuroimaging, showing its Swoop portable MRI achieved 92% concordance with high-field MRI for structural abnormality detection and 98% with clinical information. Patients preferred portable MRI 4-to-1. The company also surpassed 3,000 scans in the first year of its office-market launch. This is the first peer-reviewed real-world validation of the Swoop system in outpatient neurology, directly supporting commercial adoption. The data addresses a key barrier—clinical confidence—and could accelerate sales to independent practices. The milestone follows the FDA clearance of Optive AI software on August 20, indicating continued product momentum. Watch for revenue acceleration in Q3 earnings as scan volume grows.
At the time of this announcement, HYPR was trading at $0.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $92.2M. The 52-week trading range was $0.85 to $2.22. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.